From: In vitroantimalarial susceptibility and molecular markers of drug resistance in Franceville, Gabon
Drug | Profils | N | N° (%), of strains with polymorphism : (Pfmdr) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
N86Y | D1246Y | |||||||||
N | Y | MIX | p | D | Y | MIX | p | |||
CQ | Resistant (IC50>100 nM) | 20 | 13 (65.0%) | 6 (30.0%) | 1 (5.0%) | 0.39 | 14 (70.0%) | 2 (10.0%) | 4 (20.0%) | 0.3 |
Sensitive (IC50<100 nM) | 26 | 15 (57.7%) | 11 (42.3%) | 0 (0.0%) | Â | 18 (69.2%) | 6 (23.1%) | 2 (7.7%) | ||
MDAQ | Resistant (IC50 ≥ 60 nM) | 24 | 14 (58.3%) | 9 (37.5%) | 1 (4.2%) | 0.28 | 16 (66.7%) | 3 (12.5%) | 5 (20.8%) | 0.09 |
Sensitive (IC50 < 60 nM) | 22 | 12 (54.5%) | 10 (45.5%) | 0 (0.0%) | Â | 20 (90.9%) | 0 (0.0%) | 2 (9.1%) | ||
MF | Resistant (IC50>20 nM) | 11 | 6 (54.5%) | 5 (45.5%) | 0 (0.0%) | 0.7 | 7 (63.6%) | 2 (18.2%) | 2 (18.2%) | 0.23 |
Sensitive (IC50<20 nM) | 35 | 22 (62.8%) | 12 (34.3%) | 1 (2,9%) | Â | 28 (80.0%) | 2 (5.7%) | 5 (14.3%) | ||
DHA | Reduced susceptibility (IC50 ≥ 10 nM) | 11 | 6 (54.5%) | 5 (45.5%) | 0 (0.0%) | 0.7 | 9 (81.8%) | 1 (9.1%) | 1 (9.1%) | 0.53 |
Sensitive (IC50<10 nM) | 35 | 22 (62.8%) | 12 (34.3%) | 1 (2.9%) | Â | 27 (77.1%) | 2 (5.7%) | 6 (17.1%) |